What is semaglutide?
Semaglutide (internal code NNC0113-0217) is a 31-amino-acid GLP-1 receptor agonist developed by Novo Nordisk, engineered for extended half-life (~165 hours) through fatty-acid conjugation to albumin. This structural innovation enabled once-weekly subcutaneous dosing, a breakthrough versus earlier daily GLP-1s like liraglutide. FDA approved it as Ozempic (type 2 diabetes, December 2017), Rybelsus (oral T2D, September 2019), and Wegovy (chronic weight management, June 2021) — the trio that reshaped obesity and metabolic medicine.
In research-use-only (RUO) protocols, semaglutide is the reference single-receptor GLP-1 agonist — the baseline against which dual (tirzepatide) and triple (retatrutide) agonists are benchmarked. It is studied for body weight regulation, glycemic control, cardiovascular risk markers, NAFLD, and neuroprotective endpoints. Storage is stable lyophilized at 2–8°C; reconstituted in bacteriostatic water, solution stability reaches 56 days at 2–8°C. Lab Peptides France ships every vial with a certified COA (HPLC ≥98%) and traceable batch number.
GLP-1 receptor agonist mechanism
Gastric emptying
Slows gastric transit, extending satiety signals post-meal. Reduces food intake without caloric restriction enforcement — the appetite effect everyone feels first.
Insulin secretion
Stimulates glucose-dependent insulin release from pancreatic β-cells. Lowers HbA1c without hypoglycemia risk (unlike sulfonylureas) — the core glycemic lever.
Central appetite control
Crosses blood-brain barrier, activates hypothalamic POMC neurons, inhibits AgRP/NPY neurons. Reduces food cravings and hedonic eating signals.
Semaglutide's single-receptor GLP-1 action established the gold standard that made every dual and triple agonist possible. It remains the most clinically validated incretin in history, with millions of patient-years of safety data on Ozempic and Wegovy.
Clinical studies STEP / SUSTAIN
Wilding et al. — NEJM 2021 (STEP-1)
Phase 3 · n=1961The obesity pivot trial — 68 weeks of weekly semaglutide 2.4mg vs placebo in non-diabetic adults with BMI ≥30. The trial that triggered Wegovy's FDA approval and launched the mass-market era of GLP-1s for weight loss.
- -14.9% body weight @ 2.4mg / 68 weeks
- -2.4% body weight in placebo arm
- 86.4% of subjects lost ≥5% weight (vs 31.5% placebo)
Marso et al. — NEJM 2016 (SUSTAIN-6)
Phase 3 · CV outcomes · n=3297Cardiovascular outcomes trial in T2D patients at high CV risk, 104 weeks of weekly semaglutide (0.5 or 1.0mg) vs placebo. Established semaglutide's cardioprotective signal — later extended by the SELECT trial (Lincoff NEJM 2023) to non-diabetic obese adults.
- -26% MACE risk (primary endpoint)
- -39% non-fatal stroke
- -1.3% HbA1c (vs placebo)
SELECT 2023 and the NAFLD/NASH pipeline — Lincoff et al. 2023 (n=17604) showed semaglutide 2.4mg reduced MACE by 20% in non-diabetic obese adults — the first obesity drug to prove cardiovascular benefit. The ESSENCE trial (NASH, 2024) also demonstrated fibrosis improvement, expanding semaglutide's reach beyond weight and glycemia.
Choose your semaglutide dose
Three research formats cover every protocol — from standard escalation (5mg) to extended multi-subject studies (20mg). Each vial is HPLC ≥98%, COA-certified, shipped from France with discrete cold-chain packaging.
Sémaglutide 5mg
EntryDiscovery format — covers a short escalation protocol (6-8 weeks) at 0.25mg weekly.
View productSémaglutide 10mg
Best-sellerFlagship format — full STEP-1 escalation protocol (16 weeks, 0.25mg → 1.0mg).
View productSémaglutide 20mg
VolumeExtended format — long protocols, multi-subject, or Wegovy doses (2.4mg weekly).
View productWhy Lab Peptides France
HPLC ≥98% purity, every batch
Third-party HPLC-MS certification. COA downloadable on every product page, batch number traceable. No gray-market powder.
Stocked in France
Cold-chain packaging, discrete neutral boxes, stocked in France (no customs). Dispatches leave Tuesday and Friday, then 2 to 3 business days with Colissimo. Tracking included.
French-speaking support
Team based in Europe, replies under 4h on weekdays. Technical questions, reconstitution guidance, order tracking.
5% automatic cashback
Every paid order credits 5% of its subtotal to your loyalty balance, convertible into a promo code from 5 €. Card, Apple Pay and Google Pay accepted.
Ready to order?
Most popular research format: semaglutide 10mg. One vial covers a full 16-week escalation protocol at 0.25mg → 1.0mg weekly.
Order Semaglutide 10mgFrequently asked questions
Is semaglutide legal in France?
Yes, as a research compound (RUO) intended exclusively for laboratory use. The Novo Nordisk Ozempic/Wegovy/Rybelsus molecule is approved as a prescription medicine; in RUO, sale and possession for research are legal, but any human, veterinary, or therapeutic use is strictly prohibited outside the medical channel.
How does it differ from tirzepatide?
Semaglutide activates one receptor (GLP-1), tirzepatide activates two (GLP-1 + GIP). The SURPASS-2 trial (Frías NEJM 2021) showed tirzepatide 15mg weekly outperforms semaglutide 1mg on every metabolic endpoint. That said, semaglutide remains the most clinically validated and accessible GLP-1, with the largest safety database (SELECT, SUSTAIN, STEP, PIONEER).
How does it differ from retatrutide?
Retatrutide activates three receptors (GLP-1 + GIP + GCGR), semaglutide one only (GLP-1). Retatrutide Phase 2 data (Jastreboff NEJM 2023) show -24.2% weight at 48 weeks vs -14.9% for semaglutide 2.4mg at 68 weeks. Semaglutide however retains the advantage of being approved, with millions of patient-years of accumulated clinical data.
How to reconstitute semaglutide?
Use sterile bacteriostatic water, typical ratio 2ml per 10mg (final concentration 5mg/ml). Slowly inject water against the vial wall, do not shake, let it sit 2 minutes then gently roll. Stable 56 days at 2–8°C after reconstitution. Full detailed guide on /en/reconstitution-guide.
Which dose for a first cycle?
For a standard STEP-1 escalation protocol (0.25mg → 0.5mg → 1.0mg → 1.7mg → 2.4mg, one step every 4 weeks), the 10mg format covers the first 16 weeks. For a short exploration, 5mg is enough (6-8 weeks). 20mg is reserved for long or multi-subject protocols.
Do you ship to France? How fast?
Yes. Dispatches leave Tuesday and Friday, then allow 2 to 3 business days with Colissimo. Stocked in France, no customs. Discrete packaging, cold chain preserved, tracking included. Permanent stock on all 3 doses.
Which payment methods do you accept?
Card (Visa, Mastercard, CB), Apple Pay and Google Pay. Every paid order credits 5% of its subtotal to your loyalty balance, convertible into a promo code from 5 €.
Will I receive a Certificate of Analysis (COA)?
Every batch ships with a third-party COA (HPLC-MS, ≥98% purity), downloadable directly from the product page before purchase. Batch number is traceable.